156 related articles for article (PubMed ID: 32919086)
1. Twelve-month Continuation of the Etonogestrel Implant in Adolescents With Polycystic Ovary Syndrome.
Buyers E; Sass AE; Severn CD; Pyle L; Cree-Green M
J Pediatr Adolesc Gynecol; 2021 Feb; 34(1):33-39. PubMed ID: 32919086
[TBL] [Abstract][Full Text] [Related]
2. Twelve-month discontinuation of etonogestrel implant in an outpatient pediatric setting.
Berlan E; Mizraji K; Bonny AE
Contraception; 2016 Jul; 94(1):81-6. PubMed ID: 26948183
[TBL] [Abstract][Full Text] [Related]
3. Menstrual bleeding patterns in adolescents using etonogestrel (ENG) implant.
Deokar AM; Jackson W; Omar HA
Int J Adolesc Med Health; 2011; 23(1):75-7. PubMed ID: 21721368
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant.
Clure C; Sheeder J; Lazorwitz A
Contraception; 2024 Jul; 135():110442. PubMed ID: 38552822
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and continuation rates of the etonogestrel-subdermal contraceptive implant versus short-acting contraceptive methods offered at no cost in Campinas, Brazil.
Laporte M; Marcelino AC; da Cunha Pereira P; Espejo-Arce X; Juliato CT; Bahamondes L
Int J Gynaecol Obstet; 2024 Jul; 166(1):305-311. PubMed ID: 38328989
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen for the Treatment of Etonogestrel Implant-Associated Bleeding in an Adolescent Gynecology Practice.
Friedman JC; Buyers E; Laurin J; Hampanda K; Alaniz VI
J Pediatr Adolesc Gynecol; 2022 Jun; 35(3):341-345. PubMed ID: 34780932
[TBL] [Abstract][Full Text] [Related]
7. Timing of postpartum etonogestrel-releasing implant insertion and bleeding patterns, weight change, 12-month continuation and satisfaction rates: a randomized controlled trial.
Vieira CS; de Nadai MN; de Melo Pereira do Carmo LS; Braga GC; Infante BF; Stifani BM; Ferriani RA; Quintana SM
Contraception; 2019 Oct; 100(4):258-263. PubMed ID: 31145885
[TBL] [Abstract][Full Text] [Related]
8. Immediate postpartum etonogestrel implant: a contraception option with long-term continuation.
Wilson S; Tennant C; Sammel MD; Schreiber C
Contraception; 2014 Sep; 90(3):259-64. PubMed ID: 24993485
[TBL] [Abstract][Full Text] [Related]
9. Assessing Weight Status in Adolescent and Young Adult Users of the Etonogestrel Contraceptive Implant.
Romano ME; Braun-Courville DK
J Pediatr Adolesc Gynecol; 2019 Aug; 32(4):409-414. PubMed ID: 30928532
[TBL] [Abstract][Full Text] [Related]
10. Acceptability of long-acting, progestin-only contraception in Europe: a two-year prospective, non-interventional study.
Short M; Dallay D; Omokanye S; Stauch K; Inki P
Eur J Contracept Reprod Health Care; 2014 Feb; 19(1):29-38. PubMed ID: 24289528
[TBL] [Abstract][Full Text] [Related]
11. Treatment of rectovaginal endometriosis with the etonogestrel-releasing contraceptive implant.
Ferrero S; Scala C; Ciccarelli S; Vellone VG; Barra F
Gynecol Endocrinol; 2020 Jun; 36(6):540-544. PubMed ID: 31711348
[TBL] [Abstract][Full Text] [Related]
12. Amenorrhea in adolescents using the etonogestrel contraceptive implant.
Tsevat D; Mercier R; Bernheimer C; Lin S; Schwartz B
Contraception; 2024 May; 133():110413. PubMed ID: 38401772
[TBL] [Abstract][Full Text] [Related]
13. Migration of etonogestrel subcutaneous contraceptive implants: systematic review and recommendations for practice.
Guilbert É; Arguin H; Bélanger M
Eur J Contracept Reprod Health Care; 2024 Jun; 29(3):115-130. PubMed ID: 38712717
[TBL] [Abstract][Full Text] [Related]
14. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
[TBL] [Abstract][Full Text] [Related]
15. ENG-releasing subdermal implants in postpartum teenagers - an open-label trial study protocol.
Barbieri MM; Juliato CRT; Bahamondes L; Surita FG
Reprod Health; 2020 Jun; 17(1):100. PubMed ID: 32576199
[TBL] [Abstract][Full Text] [Related]
16. Impact of etonogestrel implant use on T-cell and cytokine profiles in the female genital tract and blood.
Haddad LB; Swaims-Kohlmeier A; Mehta CC; Haaland RE; Brown NL; Sheth AN; Chien H; Titanji K; Achilles SL; Lupo D; Hart CE; Ofotokun I
PLoS One; 2020; 15(3):e0230473. PubMed ID: 32214321
[TBL] [Abstract][Full Text] [Related]
17. Can a 3 months treatment with oral Desogestrel prior to insertion of the etonogestrel-releasing contraceptive implant improve continuation rate at 1 year? A randomized trial.
Lombardi Fäh V; Catarino R; Castillo S; Badda M; Gezer-Dickschat S; Thieringer F; Tschudin S; Viviano M; Yaron M
BMC Res Notes; 2023 Mar; 16(1):35. PubMed ID: 36915205
[TBL] [Abstract][Full Text] [Related]
18. The effect of immediate postpartum compared to delayed postpartum and interval etonogestrel contraceptive implant insertion on removal rates for bleeding.
Ireland LD; Goyal V; Raker CA; Murray A; Allen RH
Contraception; 2014 Sep; 90(3):253-8. PubMed ID: 24973904
[TBL] [Abstract][Full Text] [Related]
19. A prospective pilot study to assess the impact of the etonogestrel implant on postpartum depression.
Ross CM; Hammond C; Ralph JA; Balmert LC; Wisner KL; Kiley JW
Eur J Contracept Reprod Health Care; 2021 Apr; 26(2):98-104. PubMed ID: 33164593
[TBL] [Abstract][Full Text] [Related]
20. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
Modesto W; Bahamondes MV; Bahamondes L
Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
